The DOI matches its Crossref record; 35 of the 35 references it cites were found in a registry or an index.
Clinical and pathological features of a parkinsonian syndrome in a family with an Ala53Thr α‐synuclein mutation
Abstract
We describe an Australian family of Greek origin with a parkinsonian syndrome and an Ala53Thr α‐synuclein gene mutation. Five of 9 siblings were affected, the average age of onset was 45 years, and the initial symptoms were variable, including resting tremor, bradykinesia, and gait disturbance, as previously described in families with the same point mutation. Affected family members responded well to levodopa, developed progressive cognitive impairment, and had a disease duration of 5 to 16 years. Pathologic features typical of idiopathic Parkinson's disease were found at autopsy. However, there were several additional features not previously reported in families with this gene mutation. These features included severe central hypoventilation, orthostatic hypotension, prominent myoclonus, and urinary incontinence. An abundance of α‐synuclein–immunoreactive Lewy neurites were found in the brainstem pigmented nuclei, hippocampus, and temporal neocortex. The Lewy neurites were associated with temporal lobe vacuolation. Subcortical basal ganglia cell loss and gliosis were seen. These additional clinical and pathological features suggest that the Ala53Thr α‐synuclein mutation can produce a more widespread disorder than found in typical idiopathic Parkinson's disease. Ann Neurol 2001;49:313–319
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Mutation in the α-Synuclein Gene Identified in Families with Parkinson's Disease
Polymeropoulos, M. H., Lavedan, C., Leroy, E., Ide, S. E., Dehejia, A., Dutra, A., Pike, B., Root, H., Rubenstein, J., Boyer, R., et al. (1997) · Science · doi:10.1126/science.276.5321.2045 · Cited by 8,240
AlaSOPro mutation in the gene encoding α-synuclein in Parkinson's disease
Krüger, R., Kuhn, W., Müller, T., Woitalla, D., Graeber, M., Kösel, S., Przuntek, H., Epplen, J. T., Schols, L., & Riess, O. (1998) · Nature Genetics · doi:10.1038/ng0298-106 · Cited by 3,836
Diagnostic Criteria for Parkinson Disease
Gelb, D. J., Oliver, E., & Gilman, S. (1999) · Archives of Neurology · doi:10.1001/archneur.56.1.33 · Cited by 2,822
Masliah, E., Rockenstein, E., Veinbergs, I., Mallory, M., Hashimoto, M., Takeda, A., Sagara, Y., Sisk, A., & Mucke, L. (2000) · Science · doi:10.1126/science.287.5456.1265 · Cited by 1,765
Mapping of a gene for Parkinson's disease to chromosome 4q21-q23
Polymeropoulos, M. H., Higgins, J. J., Golbe, L. I., Johnson, W. G., Ide, S. E., Di Iorio, G., Sanges, G., Stenroos, E. S., Pho, L. T., Schaffer, A. A., et al. (1996) · Science · doi:10.1126/science.274.5290.1197 · Cited by 788
Both Familial Parkinson's Disease Mutations Accelerate α-Synuclein Aggregation
Narhi, L., Wood, S. J., Steavenson, S., Jiang, Y., Wu, G. M., Anafi, D., Kaufman, S. A., Martin, F., Sitney, K., Denis, P., et al. (1999) · Journal of Biological Chemistry · doi:10.1074/jbc.274.14.9843 · Cited by 710
A large kindred with autosomal dominant Parkinson's disease
Golbe, L. I., Di Iorio, G., Bonavita, V., Miller, D. C., & Duvoisin, R. C. (1990) · Annals of Neurology · doi:10.1002/ana.410270309 · Cited by 412
Wenning, G. K. (2000) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.68.4.434 · Cited by 260
Alpha‐synuclein in Lewy Body Disease and Alzheimer's Disease
Hashimoto, M., & Masliah, E. (1999) · Brain Pathology · doi:10.1111/j.1750-3639.1999.tb00552.x · Cited by 254
Clinical genetic analysis of Parkinson's disease in the contursi kindred
Golbe, L. I., Lazzarini, A. M., Duvoisin, R. C., Iorio, G. D., Sanges, G., Bonavita, V., & la Sala, S. (1996) · Annals of Neurology · doi:10.1002/ana.410400513 · Cited by 236
Cited by
Dauer, W., & Przedborski, S. (2003) · Neuron · doi:10.1016/s0896-6273(03)00568-3 · Cited by 5,469
Balestrino, R., & Schapira, A. H. V. (2020) · European Journal of Neurology · doi:10.1111/ene.14108 · Cited by 1,508
Anderson, J. P., Walker, D. E., Goldstein, J. M., de Laat, R., Banducci, K., Caccavello, R. J., Barbour, R., Huang, J., Kling, K., Lee, M., et al. (2006) · Journal of Biological Chemistry · doi:10.1074/jbc.m600933200 · Cited by 1,416
Alpha-synuclein and neurodegenerative diseases
Goedert, M. (2001) · Nature Reviews Neuroscience · doi:10.1038/35081564 · Cited by 1,408
Genetics of Parkinson's Disease
Klein, C., & Westenberger, A. (2012) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a008888 · Cited by 1,358
Neuronal α-Synucleinopathy with Severe Movement Disorder in Mice Expressing A53T Human α-Synuclein
Giasson, B. I., Duda, J. E., Quinn, S. M., Zhang, B., Trojanowski, J. Q., & Lee, V. M.-Y. (2002) · Neuron · doi:10.1016/s0896-6273(02)00682-7 · Cited by 1,266
Epidemiology and etiology of Parkinson's disease: a review of the evidence
Wirdefeldt, K., Adami, H.-O., Cole, P., Trichopoulos, D., & Mandel, J. (2011) · European Journal of Epidemiology · doi:10.1007/s10654-011-9581-6 · Cited by 1,199
Parkinson's disease: from monogenic forms to genetic susceptibility factors
Lesage, S., & Brice, A. (2009) · Human Molecular Genetics · doi:10.1093/hmg/ddp012 · Cited by 945
Copper in diseases and treatments, and copper‐based anticancer strategies
Tisato, F., Marzano, C., Porchia, M., Pellei, M., & Santini, C. (2010) · Medicinal Research Reviews · doi:10.1002/med.20174 · Cited by 797
G51D α‐synuclein mutation causes a novel Parkinsonian–pyramidal syndrome
Lesage, S., Anheim, M., Letournel, F., Bousset, L., Honoré, A., Rozas, N., Pieri, L., Madiona, K., Dürr, A., Melki, R., et al. (2013) · Annals of Neurology · doi:10.1002/ana.23894 · Cited by 711
Alpha‐synuclein p.H50Q, a novel pathogenic mutation for Parkinson's disease
Appel‐Cresswell, S., Vilarino‐Guell, C., Encarnacion, M., Sherman, H., Yu, I., Shah, B., Weir, D., Thompson, C., Szu‐Tu, C., Trinh, J., et al. (2013) · Movement Disorders · doi:10.1002/mds.25421 · Cited by 667
Recasens, A., Dehay, B., Bové, J., Carballo‐Carbajal, I., Dovero, S., Pérez‐Villalba, A., Fernagut, P., Blesa, J., Parent, A., Perier, C., et al. (2014) · Annals of Neurology · doi:10.1002/ana.24066 · Cited by 632
What Genetics Tells us About the Causes and Mechanisms of Parkinson's Disease
Corti, O., Lesage, S., & Brice, A. (2011) · Physiological Reviews · doi:10.1152/physrev.00022.2010 · Cited by 611
Animal models of Parkinson's disease
Betarbet, R., Sherer, T. B., & Greenamyre, J. T. (2002) · BioEssays · doi:10.1002/bies.10067 · Cited by 592
The epidemiology of dementia associated with Parkinson disease
Aarsland, D., & Kurz, M. W. (2010) · Journal of the Neurological Sciences · doi:10.1016/j.jns.2009.08.034 · Cited by 578
Altered proteasomal function in sporadic Parkinson’s disease
St. P. McNaught, K., Belizaire, R., Isacson, O., Jenner, P., & Olanow, C. W. (2003) · Experimental Neurology · doi:10.1006/exnr.2002.8050 · Cited by 573
The Synucleinopathies: Twenty Years On
Goedert, M., Jakes, R., & Spillantini, M. G. (2017) · Journal of Parkinson’s Disease · doi:10.3233/jpd-179005 · Cited by 569
Neuropathology, biochemistry, and biophysics of α‐synuclein aggregation
Uversky, V. N. (2007) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2007.04764.x · Cited by 567
Nuytemans, K., Theuns, J., Cruts, M., & Van Broeckhoven, C. (2010) · Human Mutation · doi:10.1002/humu.21277 · Cited by 563
Kachergus, J., Mata, I. F., Hulihan, M., Taylor, J. P., Lincoln, S., Aasly, J., Gibson, J. M., Ross, O. A., Lynch, T., Wiley, J., et al. (2005) · The American Journal of Human Genetics · doi:10.1086/429256 · Cited by 541
Failure of the ubiquitin-proteasome system in Parkinson’s disease
McNaught, K. S. P., Olanow, C. W., Halliwell, B., Isacson, O., & Jenner, P. (2001) · Nature Reviews Neuroscience · doi:10.1038/35086067 · Cited by 519
Genetics in Parkinson disease: Mendelian versus non‐Mendelian inheritance
Hernandez, D. G., Reed, X., & Singleton, A. B. (2016) · Journal of Neurochemistry · doi:10.1111/jnc.13593 · Cited by 448
“Eight additional families, located in central and southwestern Greece, were also confirmed to have mutations in a-synuclein, suggesting the presence of a founder mutation (Athanassiadou et al. 1999; Spira et al. 2001).”
BackgroundEdwards, T. L., Scott, W. K., Almonte, C., Burt, A., Powell, E. H., Beecham, G. W., Wang, L., Züchner, S., Konidari, I., Wang, G., et al. (2010) · Annals of Human Genetics · doi:10.1111/j.1469-1809.2009.00560.x · Cited by 465
Neuropathology of sporadic Parkinson's disease: Evaluation and changes of concepts
Jellinger, K. A. (2012) · Movement Disorders · doi:10.1002/mds.23795 · Cited by 451
Kiely, A. P., Asi, Y. T., Kara, E., Limousin, P., Ling, H., Lewis, P., Proukakis, C., Quinn, N., Lees, A. J., Hardy, J., et al. (2013) · Acta Neuropathologica · doi:10.1007/s00401-013-1096-7 · Cited by 451
Identification and Rescue of α-Synuclein Toxicity in Parkinson Patient–Derived Neurons
Chung, C. Y., Khurana, V., Auluck, P. K., Tardiff, D. F., Mazzulli, J. R., Soldner, F., Baru, V., Lou, Y., Freyzon, Y., Cho, S., et al. (2013) · Science · doi:10.1126/science.1245296 · Cited by 441
Oxidative Stress and the Pathogenesis of Neurodegenerative Disorders
Reynolds, A., Laurie, C., Lee Mosley, R., & Gendelman, H. E. (2007) · International Review of Neurobiology · doi:10.1016/s0074-7742(07)82016-2 · Cited by 432
Clinical Approach to Parkinson's Disease: Features, Diagnosis, and Principles of Management
Massano, J., & Bhatia, K. P. (2012) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a008870 · Cited by 422
SIRT1 and SIRT2: emerging targets in neurodegeneration
Donmez, G., & Outeiro, T. F. (2013) · EMBO Molecular Medicine · doi:10.1002/emmm.201302451 · Cited by 411
Phenotypic variation in a large Swedish pedigree due to SNCA duplication and triplication
Fuchs, J., Nilsson, C., Kachergus, J., Munz, M., Larsson, E.-M., Schüle, B., Langston, J. W., Middleton, F. A., Ross, O. A., Hulihan, M., et al. (2007) · Neurology · doi:10.1212/01.wnl.0000254458.17630.c5 · Cited by 397
Parkinson's Disease and Alpha Synuclein: Is Parkinson's Disease a Prion‐Like Disorder?
Olanow, C. W., & Brundin, P. (2013) · Movement Disorders · doi:10.1002/mds.25373 · Cited by 390
Synaptopathies: synaptic dysfunction in neurological disorders – A review from students to students
Lepeta, K., Lourenco, M. V., Schweitzer, B. C., Martino Adami, P. V., Banerjee, P., Catuara‐Solarz, S., de La Fuente Revenga, M., Guillem, A. M., Haidar, M., Ijomone, O. M., et al. (2016) · Journal of Neurochemistry · doi:10.1111/jnc.13713 · Cited by 386
Epidemiological, clinical, and genetic characteristics of early-onset parkinsonism
Schrag, A., & Schott, J. M. (2006) · The Lancet Neurology · doi:10.1016/s1474-4422(06)70411-2 · Cited by 384
The E46K Mutation in α-Synuclein Increases Amyloid Fibril Formation
Greenbaum, E. A., Graves, C. L., Mishizen-Eberz, A. J., Lupoli, M. A., Lynch, D. R., Englander, S. W., Axelsen, P. H., & Giasson, B. I. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m411638200 · Cited by 370
Neuronal cell death in neurodegenerative diseases: recurring themes around protein handling
Gorman, A. M. (2008) · Journal of Cellular and Molecular Medicine · doi:10.1111/j.1582-4934.2008.00402.x · Cited by 362
A possible role for humoral immunity in the pathogenesis of Parkinson's disease
Orr, C. F., Rowe, D. B., Mizuno, Y., Mori, H., & Halliday, G. M. (2005) · Brain · doi:10.1093/brain/awh625 · Cited by 350
Self-citationProposed neuropathological criteria for the post mortem diagnosis of multiple system atrophy
Trojanowski, J. Q., Revesz, T., & the Neuropathology Working Group on MSA (2007) · Neuropathology and Applied Neurobiology · doi:10.1111/j.1365-2990.2007.00907.x · Cited by 349
Genomic investigation of α‐synuclein multiplication and parkinsonism
Ross, O. A., Braithwaite, A. T., Skipper, L. M., Kachergus, J., Hulihan, M. M., Middleton, F. A., Nishioka, K., Fuchs, J., Gasser, T., Maraganore, D. M., et al. (2008) · Annals of Neurology · doi:10.1002/ana.21380 · Cited by 342
Neuropathology of genetic synucleinopathies with parkinsonism: Review of the literature
Schneider, S. A., & Alcalay, R. N. (2017) · Movement Disorders · doi:10.1002/mds.27193 · Cited by 342
Ono, K., & Yamada, M. (2006) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2006.03707.x · Cited by 320
The genetics and neuropathology of Parkinson’s disease
Houlden, H., & Singleton, A. B. (2012) · Acta Neuropathologica · doi:10.1007/s00401-012-1013-5 · Cited by 316
The physiological role of α‐synuclein and its relationship to Parkinson’s Disease
Sulzer, D., & Edwards, R. H. (2019) · Journal of Neurochemistry · doi:10.1111/jnc.14810 · Cited by 312
The neuropathology of genetic Parkinson's disease
Poulopoulos, M., Levy, O. A., & Alcalay, R. N. (2012) · Movement Disorders · doi:10.1002/mds.24962 · Cited by 311
McNaught, K. S. P., Mytilineou, C., JnoBaptiste, R., Yabut, J., Shashidharan, P., Jenner, P., & Olanow, C. W. (2002) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.2002.00821.x · Cited by 304
Genetics of Parkinson's disease and parkinsonism
Hardy, J., Cai, H., Cookson, M. R., Gwinn‐Hardy, K., & Singleton, A. (2006) · Annals of Neurology · doi:10.1002/ana.21022 · Cited by 303
α‐Synuclein oligomers and clinical implications for Parkinson disease
Kalia, L. V., Kalia, S. K., McLean, P. J., Lozano, A. M., & Lang, A. E. (2013) · Annals of Neurology · doi:10.1002/ana.23746 · Cited by 292
Cell death pathways in Parkinson’s disease: proximal triggers, distal effectors, and final steps
Levy, O. A., Malagelada, C., & Greene, L. A. (2009) · Apoptosis · doi:10.1007/s10495-008-0309-3 · Cited by 287
Mitochondria and degenerative disorders
Orth, M., & Schapira, A. H. V. (2001) · American Journal of Medical Genetics · doi:10.1002/ajmg.1425 · Cited by 280
Rideout, H. J., Larsen, K. E., Sulzer, D., & Stefanis, L. (2001) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.2001.00474.x · Cited by 274
Proteasome inhibition causes nigral degeneration with inclusion bodies in rats
McNaught, K. S. P., Bj??rklund, L. M., Belizaire, R., Isacson, O., Jenner, P., & Olanow, C. W. (2002) · Neuroreport · doi:10.1097/00001756-200208070-00018 · Cited by 274
Wang, Y., Spincemaille, P., Liu, Z., Dimov, A., Deh, K., Li, J., Zhang, Y., Yao, Y., Gillen, K. M., Wilman, A. H., et al. (2017) · Journal of Magnetic Resonance Imaging · doi:10.1002/jmri.25693 · Cited by 273
Wiltfang, J., Esselmann, H., Bibl, M., Smirnov, A., Otto, M., Paul, S., Schmidt, B., Klafki, H. ‐., Maler, M., Dyrks, T., et al. (2002) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.2002.00818.x · Cited by 271
Aging and Parkinson's disease: Different sides of the same coin?
Collier, T. J., Kanaan, N. M., & Kordower, J. H. (2017) · Movement Disorders · doi:10.1002/mds.27037 · Cited by 268
Cerebrospinal fluid lysosomal enzymes and alpha‐synuclein in Parkinson's disease
Parnetti, L., Chiasserini, D., Persichetti, E., Eusebi, P., Varghese, S., Qureshi, M. M., Dardis, A., Deganuto, M., De Carlo, C., Castrioto, A., et al. (2014) · Movement Disorders · doi:10.1002/mds.25772 · Cited by 266
Interface between tauopathies and synucleinopathies: A tale of two proteins
Galpern, W. R., & Lang, A. E. (2006) · Annals of Neurology · doi:10.1002/ana.20819 · Cited by 263
The second brain and Parkinson’s disease
Lebouvier, T., Chaumette, T., Paillusson, S., Duyckaerts, C., Bruley des Varannes, S., Neunlist, M., & Derkinderen, P. (2009) · European Journal of Neuroscience · doi:10.1111/j.1460-9568.2009.06873.x · Cited by 261
Autophagy and Alpha‐Synuclein: Relevance to Parkinson's Disease and Related Synucleopathies
Xilouri, M., Brekk, O. R., & Stefanis, L. (2016) · Movement Disorders · doi:10.1002/mds.26477 · Cited by 261
The Role of α-Synuclein Oligomers in Parkinson’s Disease
Du, X.-Y., Xie, X.-X., & Liu, R.-T. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21228645 · Cited by 234
Proteolytic stress: A unifying concept for the etiopathogenesis of Parkinson’s disease
McNaught, K. S. P., & Olanow, C. W. (2003) · Annals of Neurology · doi:10.1002/ana.10512 · Cited by 203
Gut–brain axis and the spread of α‐synuclein pathology: Vagal highway or dead end?
Breen, D. P., Halliday, G. M., & Lang, A. E. (2019) · Movement Disorders · doi:10.1002/mds.27556 · Cited by 193
Self-citationLam, H. A., Wu, N., Cely, I., Kelly, R. L., Hean, S., Richter, F., Magen, I., Cepeda, C., Ackerson, L. C., Walwyn, W., et al. (2011) · Journal of Neuroscience Research · doi:10.1002/jnr.22611 · Cited by 184
Ben Gedalya, T., Loeb, V., Israeli, E., Altschuler, Y., Selkoe, D. J., & Sharon, R. (2009) · Traffic · doi:10.1111/j.1600-0854.2008.00853.x · Cited by 169
Schildknecht, S., Gerding, H. R., Karreman, C., Drescher, M., Lashuel, H. A., Outeiro, T. F., Di Monte, D. A., & Leist, M. (2013) · Journal of Neurochemistry · doi:10.1111/jnc.12226 · Cited by 148
Park, J., Kim, K. S., Lee, S., Ryu, J., Chung, K. C., Choo, Y., Jou, I., Kim, J., & Park, S. M. (2009) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2009.06150.x · Cited by 135
In vivo gastric detection of α-synuclein inclusions in Parkinson's disease
Sánchez‐Ferro, Á., Rábano, A., Catalán, M. J., Rodríguez‐Valcárcel, F. C., Díez, S. F., Herreros‐Rodríguez, J., García‐Cobos, E., Álvarez‐Santullano, M. M., López‐Manzanares, L., Mosqueira, A. J., et al. (2015) · Movement Disorders · doi:10.1002/mds.25988 · Cited by 123
Molecular Mechanisms Underlying Synaptic and Axon Degeneration in Parkinson’s Disease
Gcwensa, N. Z., Russell, D. L., Cowell, R. M., & Volpicelli-Daley, L. A. (2021) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2021.626128 · Cited by 110
DJ‐1 deficiency impairs autophagy and reduces alpha‐synuclein phagocytosis by microglia
Nash, Y., Schmukler, E., Trudler, D., Pinkas‐Kramarski, R., & Frenkel, D. (2017) · Journal of Neurochemistry · doi:10.1111/jnc.14222 · Cited by 100
Herradón, G., & Pérez‐García, C. (2014) · British Journal of Pharmacology · doi:10.1111/bph.12312 · Cited by 88
Increased CSF α‐synuclein levels in Alzheimer's disease: Correlation with tau levels
Slaets, S., Vanmechelen, E., Le Bastard, N., Decraemer, H., Vandijck, M., Martin, J., De Deyn, P. P., & Engelborghs, S. (2014) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2013.10.004 · Cited by 85
Stimulatory effect of α‐synuclein on the tau‐phosphorylation by GSK‐3 β
Kawakami, F., Suzuki, M., Shimada, N., Kagiya, G., Ohta, E., Tamura, K., Maruyama, H., & Ichikawa, T. (2011) · The FEBS Journal · doi:10.1111/j.1742-4658.2011.08389.x · Cited by 82
Cheng, F., Li, X., Li, Y., Wang, C., Wang, T., Liu, G., Baskys, A., Uéda, K., Chan, P., & Yu, S. (2011) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2011.07460.x · Cited by 73
Marx, F. P., Soehn, A. S., Berg, D., Melle, C., Schiesling, C., Lang, M., Kautzmann, S., Strauss, K. M., Franck, T., Engelender, S., et al. (2007) · The FASEB Journal · doi:10.1096/fj.06-6734com · Cited by 52
Peters, S. T., Fahrenkopf, A., Choquette, J. M., Vermilyea, S. C., Lee, M. K., & Vossel, K. (2020) · Frontiers in Neurology · doi:10.3389/fneur.2020.00563 · Cited by 29
Metadata
- Authors
- Spira, P. J., Sharpe, D. M., Halliday, G., Cavanagh, J., & Nicholson, G. A.
- Venue
- Annals of Neurology
- Publisher
- Wiley
- Published
- 2001-03
- Volume
- 49
- Issue
- 3
- Pages
- 313-319
- ISSN
- 0364-5134 (ISSN-L)
- 1531-8249
- OpenAlex
- W4297407199
- Cited by
- 627
- References
- 35
- FWCI
- 12.83
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.